Sılay Kamile, Uçar Gökhan, Eren Tülay, Selvi Öztorun Hande, Yazıcı Ozan, Özdemir Nuriye
Department of Geriatrics, Faculty of Medicine, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, 06800 Ankara, Türkiye.
Department of Medical Oncology, Ankara Bilkent City Hospital, 06800 Ankara, Türkiye.
J Clin Med. 2025 Jan 22;14(3):711. doi: 10.3390/jcm14030711.
Sarcopenia, which is characterized by the progressive loss of skeletal muscle mass, strength, and functionality, adversely affects cancer outcomes. This study aims to evaluate the development and progression of sarcopenia in patients with gastrointestinal cancer undergoing chemotherapy and its impact on comprehensive geriatric assessment outcomes in older participants. This cross-sectional study included 351 gastrointestinal cancer patients from October 2018 to December 2019. Pre- and post-chemotherapy measurements were taken for 243 participants. Sarcopenia was assessed using EWGSOP-2 criteria, including muscle mass, strength, and performance evaluations. A comprehensive geriatric assessment was conducted for patients aged 65 years and older. The median age of participants was 57.84 years, with 31.7% being female and 29.2% being aged 65 years or older. A significant increase in the prevalence of sarcopenia post-chemotherapy was observed. The factors significantly associated with sarcopenia included low hand grip strength (-0.264; < 0.001) and slow gait speed (0.222; = 0.007). The muscle mass and albumin levels of older patients declined significantly post-treatment. This study highlights a strong association between chemotherapy and sarcopenia in gastrointestinal cancer patients, emphasizing the need for early detection and tailored interventions. Comprehensive geriatric assessments can provide critical insights that improve patient outcomes during chemotherapy.
肌肉减少症以骨骼肌质量、力量和功能的逐渐丧失为特征，对癌症治疗结果产生不利影响。本研究旨在评估接受化疗的胃肠道癌症患者肌肉减少症的发展和进展情况，及其对老年参与者综合老年评估结果的影响。这项横断面研究纳入了2018年10月至2019年12月期间的351例胃肠道癌症患者。对243名参与者进行了化疗前后的测量。采用EWGSOP-2标准评估肌肉减少症，包括肌肉质量、力量和功能评估。对65岁及以上的患者进行了综合老年评估。参与者的中位年龄为57.84岁，女性占31.7%，65岁及以上者占29.2%。化疗后肌肉减少症的患病率显著增加。与肌肉减少症显著相关的因素包括握力低（-0.264；<0.001）和步态速度慢（0.222；=0.007）。老年患者治疗后的肌肉质量和白蛋白水平显著下降。本研究强调了化疗与胃肠道癌症患者肌肉减少症之间的密切关联，强调了早期检测和针对性干预的必要性。综合老年评估可以提供关键的见解，改善化疗期间的患者治疗结果。
